 |
인쇄하기
취소
|
Dong-A’s Stillen enjoys robust sales in first half
Dong-A Pharm says its Stillen garnered 40 billion won in the domestic ulceration drug market for the January-June period of this year, up a whopping 145 percent compared with the same period a year earlier.
The market's No. 2 player Jeil Pharm reached a 15.1 billion won in Lanston sales, followed by Otsuka’s Mucosta with 12 billion won.
The homegrown drug in Korea will not be as stable as...
The market's No. 2 player Jeil Pharm reached a 15.1 billion won in Lanston sales, followed by Otsuka’s Mucosta with 12 billion won.
The homegrown drug in Korea will not be as stable as...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.